Insights On Drug Development

  1. Simplifying Antibody-Drug Conjugate Payload Synthesis 8/5/2025

    ADC's offer precise, targeted therapy by delivering cytotoxic agents directly to diseased cells. Learn how this method minimizes harm to healthy tissue and revolutionizes treatment for cancer.

  2. Site-Specific Conjugation For Next-Gen ADCs 8/4/2025

    Unlock the full potential of your ADCs with a site-specific conjugation platform that delivers unmatched stability, homogeneity, and therapeutic performance.

  3. Optimizing Cell Therapy Analytics Through DoE Methodologies 8/4/2025

    Design of Experiment (DoE) methods streamline the development of robust, phase-appropriate potency and functional assays, ensuring testing that supports scalable cell therapy development.

  4. Accelerated Tech Transfer With Integrated, Client-Focused Project Management 7/30/2025

    Observe how integrated project management and co-located DS/DP operations streamline technology transfer, reduce risks, and accelerate biopharmaceutical development timelines.

  5. Leveraging Technology For Rapid Clinical Material Delivery 7/29/2025

    Discover how one family's collaboration with a specialized CDMO enabled the rapid development of a life-saving gene therapy for their daughter diagnosed with an ultra-rare disease.

  6. Gene Therapy In-Use And Device Compatibility Studies 7/28/2025

    Discover an essential aspect of development that ensures gene therapy products remain safe, stable, and effective throughout preparation and administration by simulating real-world clinical conditions.

  7. Next Generation Sequencing In Viral Safety Testing 7/25/2025

    Next Generation Sequencing (NGS) offers a sensitive, high-throughput solution for detecting adventitious viral agents (AVAs), improving biopharmaceutical safety and accelerating regulatory-compliant product development.

  8. AAV Viral Titering Using Nanoplate-Based Digital PCR 7/22/2025

    Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.

  9. New Purpose-Built Facility For Large-Scale Sterile Fill/Finish Operations 7/17/2025

    Expanding capacity for late-phase clinical and large-scale commercial small molecule and biologic drugs, a new facility boosts sterile fill/finish capabilities.

  10. Analytical Strategies For Impurity Control In Antibody-Drug Conjugates 7/16/2025

    Antibody-drug conjugates (ADCs) combine antibody targeting with potent cytotoxic payloads to treat resistant cancers, but their complexity requires phase-appropriate analytical strategies.